CanSino Biologics. has filed a patent for a method of preparing an adenovirus vector vaccine using a perfusion culture process. The method involves adjusting the perfusion rate based on cell density to increase the yield and specific activity of the virus. The patent claims a specific method for culturing adenovirus host cells, including steps for inoculation and adjusting the perfusion rate at different cell densities. GlobalData’s report on CanSino Biologics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on CanSino Biologics, LPS antibody-based anti-bacterials was a key innovation area identified from patents. CanSino Biologics's grant share as of September 2023 was 24%. Grant share is based on the ratio of number of grants to total number of patents.
Method for preparing an adenovirus vector vaccine using perfusion culture
A recently filed patent (Publication Number: US20230313225A1) describes methods for culturing an adenovirus host cell and producing an adenovirus. The patent claims a method for culturing an adenovirus host cell, which involves inoculating host cells for cell culture and starting perfusion at a perfusion rate of 1-3 VVD (vessel volume per day) after the cell density reaches 1×106-5×106 cells/mL. The perfusion rate is then adjusted to 2-4 VVD after the cell density grows to 5×106-10×106 cells/mL.
The patent also claims a method for producing an adenovirus, which includes the same steps as the method for culturing an adenovirus host cell, but additionally involves inoculating virus for culture. In this method, the culture is a perfusion culture at a perfusion rate of 1-3 VVD.
Both methods utilize a continuous perfusion device with an alternating tangential flow filtration system, where the filtration pore size of a hollow fiber column is 0.1-0.8 µm. The concentration of glutamine in the cell culture is maintained at 2 mM or more.
The host cell used in these methods is a 293 cell, specifically an HEK293 cell or an HEK293.CS cell. The adenovirus produced can be a human adenovirus or a chimpanzee adenovirus, and it can be selected from various types including AdHu5, AdHu4, AdHu7, AdHu11, AdHu26, AdHu55, AdC68, and AdC3.
Furthermore, the patent claims a method for preparing an adenovirus vector vaccine, which involves the same steps as the method for producing an adenovirus. The concentration of glutamine in the cell culture is also maintained at 2 mM or more, and the host cell used is a 293 cell, specifically an HEK293 cell or an HEK293.CS cell.
Overall, this patent describes methods for culturing an adenovirus host cell, producing an adenovirus, and preparing an adenovirus vector vaccine. These methods involve specific steps, including perfusion at certain rates, the use of a continuous perfusion device with a specific filtration system, and the maintenance of a minimum concentration of glutamine in the cell culture. The host cell used is a 293 cell, and the adenovirus produced can be a human or chimpanzee adenovirus, with various types available. Additionally, the adenovirus can be a recombinant adenovirus containing a coding exogenous gene, such as a gene of a structural protein of SARS-CoV-2.
To know more about GlobalData’s detailed insights on CanSino Biologics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
